MedTrace Logo

Amping up With PemJAK

NCT07283822 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-12-16

No results posted yet for this study

Summary

The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

Conditions

  • Non-Hodgkin Lymphoma
  • Hodgkin Disease Lymphoma
  • Non-Hodgkin Lymphoma Refractory/ Relapsed
  • Hodgkin Disease Recurrent
  • Gray Zone Lymphoma
  • Peripheral T-cell Lymphoma
  • Cutaneous T-Cell Lymphomas
  • Primary Mediastinal B Cell Lymphoma

Interventions

DRUG

Ruxolitinib

Patients will receive the study drug ruxolitinib for as long as the disease responds, for up to a maximum of one year (or 17 cycles). After study treatment with ruxolitinib is finished, the study doctor will continue to watch for side effects and follow the condition for one year. If any side effects are experienced, the study doctor will follow up until resolution or stabilization of the side effect.

DRUG

Pembrolizumab

Pembrolizumab immunotherapy will be administered intravenously at 200 mg once every 21 days. Subjects will receive pembrolizumab for as long as the disease responds, up to a maximum of one year (or 17 cycles). Each cycle is 21 days long.

Sponsors & Collaborators

Principal Investigators

  • Seda Tolu, MD · Columbia University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-03
Primary Completion
2028-01-31
Completion
2029-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07283822 on ClinicalTrials.gov